- Previous Close
175.23 - Open
182.99 - Bid --
- Ask --
- Day's Range
182.99 - 192.48 - 52 Week Range
155.00 - 369.70 - Volume
561,755 - Avg. Volume
159,457 - Market Cap (intraday)
9.19B - Beta (5Y Monthly) 0.68
- PE Ratio (TTM)
19.30 - EPS (TTM)
9.85 - Earnings Date May 14, 2025 - May 19, 2025
- Forward Dividend & Yield 3.00 (1.62%)
- Ex-Dividend Date Sep 2, 2024
- 1y Target Est
--
Kopran Limited, an integrated pharmaceutical company, engages in the manufacture and marketing of active pharmaceutical ingredients and finished dosage forms in India and internationally. The company offers its products in various dosage forms, including tablets, capsules, syrups, dry powder, suspension, and injectables, as well as branded and generic formulations. It also provides drugs in the categories of macrolide, antibacterial, anticonvulsant, anti-hypertensive, anti-helmentics, anti-acne, anti-infective, anti-thrombotic, antidiabetic, pain management, neuromodular, gastroenterology, and cardiovascular. In addition, the company provides drugs for erectile dysfunction, antiallergics, respiratory, oncology, central nervous system, antiprotozoal, anthelmintics, antipeptic ulcer and gut, and others. Kopran Limited was incorporated in 1958 and is based in Mumbai, India.
www.kopran.com842
Full Time Employees
March 31
Fiscal Year Ends
Sector
Industry
Recent News: KOPRAN.NS
View MorePerformance Overview: KOPRAN.NS
Trailing total returns as of 4/11/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: KOPRAN.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: KOPRAN.NS
View MoreValuation Measures
Market Cap
8.47B
Enterprise Value
9.63B
Trailing P/E
17.79
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.32
Price/Book (mrq)
1.70
Enterprise Value/Revenue
1.51
Enterprise Value/EBITDA
11.24
Financial Highlights
Profitability and Income Statement
Profit Margin
7.38%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
6.43B
Net Income Avi to Common (ttm)
474.95M
Diluted EPS (ttm)
9.85
Balance Sheet and Cash Flow
Total Cash (mrq)
83.05M
Total Debt/Equity (mrq)
24.96%
Levered Free Cash Flow (ttm)
--